| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
LBRX
LB Pharmaceuticals, Inc.
|
Jun 11, 2026 | BUY |
Strong Buy
+50.1% avg upside
7 analysts
|
$36.00
20.90% Upside
|
-2.3% |
|
IMNM
Immunome
|
Jun 11, 2026 | BUY |
Strong Buy
+83.0% avg upside
16 analysts
|
$36.00
97.31% Upside
|
+0.9% |
|
MPLT
MapLight Therapeutics, Inc.
|
May 21, 2026 | BUY |
Strong Buy
+33.1% avg upside
11 analysts
|
$43.00
43.86% Upside
|
-7.2% |
|
DSGN
Design Therapeutics
|
May 19, 2026 | BUY |
Strong Buy
+45.3% avg upside
9 analysts
|
$22.00
82.22% Upside
|
· |
|
ACRS
Aclaris Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+122.5% avg upside
15 analysts
|
$10.00
126.77% Upside
|
-11.1% |
|
HIT
Health In Tech, Inc. Class A
|
Apr 10, 2026 | BUY |
Strong Buy
+270.3% avg upside
3 analysts
|
— | +8.2% |
|
APGE
Apogee Therapeutics
|
Mar 24, 2026 | BUY |
Strong Buy
+28.7% avg upside
19 analysts
|
$114.00
30.13% Upside
|
+21.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.